Long-term prognosis of patients with myocarditis attributed to Covid-19 mRNA vaccination, SARS-CoV-2 infection, or conventional etiologies (26 August 2024)

Summary

This French cohort study looked at the long-term prognosis of myocarditis after Covid-19 mRNA vaccination. It aimed to assess whether clinical outcomes and medical management differ from myocarditis following Covid infection and other origins. Using data from the French National Health Data System, all individuals aged 12 to 49 years hospitalised for myocarditis in France between December 27, 2020 and June 30, 2022 were included in the study. The authors found that people with post-vaccine myocarditis had less severe cardiovascular events than those with myocarditis of other origins at 18 months of follow-up. However, they stress that affected patients, mainly healthy young men, may require medical management up to several months after hospital discharge.